As we look toward 2025, the clinical trials industry is expanding at a remarkable pace, projected to grow from $81.9 billion in 2023 to approximately $92.4 billion by 2025, with long-term growth expected to reach $153.59 billion by 2033. This upward trajectory presents both challenges and unique opportunities for smaller and mid-sized Contract Research Organisations (CROs) and biotech companies. To succeed in this competitive landscape, these organisations can leverage advanced technologies, such as AI-driven recruitment and specialised trial methodologies, especially in high-demand areas like oncology. Here’s how smaller CROs can strategically position themselves for success.
What’s Shaping the Clinical Trials Market in 2025?
Several key trends are expected to drive clinical trials in the coming years, reshaping strategies and emphasising adaptability:
Oncology Takes Center Stage: Cancer research is anticipated to account for about 35% of all clinical trials by 2025, fueled by breakthroughs in immunotherapy and precision oncology. This makes oncology a critical specialisation area, with growing demand for CROs adept at managing complex cancer trials.
Rise of Decentralised Trials: Nearly 70% of clinical trials are projected to include decentralised elements, making trials more accessible for patients. However, this model also requires digital capabilities and robust data management, an area where agile CROs can lead the way.
Focus on Rare Diseases: Rare disease trials are expected to grow by 15% annually, driven by increased investment and demand for specialised expertise. Smaller CROs focusing on rare diseases can find valuable niches here, where personalisation and attention to detail are essential.
The Unique Edge of Smaller CROs
Smaller CROs and biotech firms have unique strengths that can set them apart from industry giants. Leaner teams and a flexible structure enable them to:
- Be Agile: Smaller organisations can quickly pivot to adopt new technology or refine study protocols.
- Build Strong Client Relationships: They often deliver a level of personalised service that larger organisations struggle to match.
- Specialise Deeply: By focusing on specific therapeutic areas, like oncology or rare diseases, they build targeted expertise that appeals to niche markets.
Leveraging AI for Competitive Advantage
Artificial Intelligence is transforming clinical trials, especially in areas like patient recruitment and trial management. Here’s how smaller CROs can use AI to enhance their offerings:
- Efficient Patient Recruitment: AI-driven recruitment platforms streamline the process by analysing patient data to quickly identify eligible trial participants. The Tufts Center for the Study of Drug Development found that these tools can reduce recruitment times by 30%, helping avoid costly delays and maximising patient engagement.
- Predictive Analytics for Site Selection: Data-driven site selection, often supported by AI, allows CROs to predict high-performing trial sites based on historical data. This approach reduces site activation times by up to 25%, which is crucial for maximising limited resources and enhancing trial efficiency.
- Enhanced Protocol Design with NLP: NLP tools streamline protocol development by reviewing past trial amendments and optimising criteria. Clinical Leader reports that this can cut amendments by 50%, reducing costs and accelerating trial timelines.
Oncology: A Key Growth Area
The oncology trial market, forecasted to reach $16.4 billion by 2025, presents significant opportunities. Here’s how CROs can leverage AI to meet the needs of this high-growth sector:
- Precision Medicine Trials: Precision oncology requires identifying patients with specific genetic markers. AI simplifies this process by analysing patient data for genetic matches, helping CROs support highly specialised trials.
- Immuno-Oncology Trials: As the global immunotherapy market is projected to reach $115.4 billion by 2025, demand for related trials is growing. Smaller CROs can tap into this trend by developing expertise in conducting immuno-oncology trials.
- Combination Therapy Trials: AI-driven analytics help design complex trials for combination therapies, where different drugs are tested together. By optimising trial design, CROs can reduce the challenges associated with managing these multifaceted studies.
Preparing for 2025: Practical Takeaways
For smaller CROs and biotech companies aiming to thrive in the evolving clinical trial landscape, here are some key strategies:
- Embrace Technology: AI tools are rapidly becoming essential in clinical trials. Investing in AI-powered recruitment, site selection, and protocol optimisation will enhance efficiency and reduce costs.
- Build a Niche: Specialisation in high-demand areas like oncology, rare diseases, or decentralised trials can set your organisation apart and drive more business.
- Prioritise Flexibility: Smaller organisations can often adapt more quickly than larger counterparts. Use this to your advantage to test new trial models or adopt cutting-edge technologies ahead of the competition.
Looking Ahead: The Role of AI-Driven Platforms Like Srotas Health
With the right combination of technology, specialisation, and agility, smaller CROs and biotech companies can thrive in 2025’s competitive clinical trial market.
AI-driven platforms like Srotas Health, built using proprietary Clinical Large Language Models (LLMs), provide powerful tools to address challenges in high-growth areas like oncology.
By embracing these technologies and focusing on specialised niches, smaller players can make a substantial impact—bringing innovative therapies to patients faster and more efficiently than ever.
Ready to transform your clinical trial recruitment? Reach out to Srotas Health today to explore how our advanced AI solutions can drive efficiency and value for your next clinical trial.
Authored by: Suman Bhaskaran Vikram Parimi
References:
https://www.novaoneadvisor.com/report/clinical-trials-market
https://www.biospace.com/clinical-trials-market-size-to-increase-usd-153-59-billion-by-2033
Thanks for reading. Check back soon for more updates!